Advertisement
BIIB vs MRK
Which Stock Would AI Choose? Biogen Inc. (BIIB) vs. Merck & Co., Inc. (MRK) Stock Comparison
Key Takeaways
- BIIB has outperformed MRK over the past year with approximately 51% gains compared to 29%, driven by pipeline optimism.
- Recent market activity shows MRK experiencing an 8-9% pullback in the past month, while BIIB remained relatively flat.
- MRK boasts a larger market capitalization of about $272 billion and higher profit margins around 28%, reflecting its diversified pharma stability.
- Year-to-date returns are similar at roughly 4-5% for both stocks amid sector volatility.
- Analyst upgrades for BIIB, including UBS to Buy with a $225 target, highlight upcoming pipeline catalysts.
- MRK offers a reliable dividend yield of 3.09% and stronger long-term returns.
Introduction
This stock comparison pits BIIB, a biotech leader focused on neurological disorders, against MRK, a diversified pharmaceutical giant with blockbuster oncology and vaccine franchises. Both operate in the healthcare sector but differ in scale, risk profiles, and growth drivers. Traders seeking short-term momentum or investors prioritizing stability and dividends may find value in analyzing their relative performance, recent catalysts, and market positioning in today's volatile environment.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) specializes in therapies for neurological conditions, including multiple sclerosis (MS) and Alzheimer's disease. In recent market activity, BIIB shares have shown resilience, trading around $183 with a year-to-date gain of 4.2% and a robust 51% rise over the past year. The stock's P/E ratio (price-to-earnings ratio) stands at about 21, with a market cap of $27 billion. Sentiment has been bolstered by analyst upgrades, such as UBS raising its target to $225 citing a "slew of pipeline catalysts" into 2027, including new launches potentially offsetting declines in its MS portfolio. However, ongoing revenue pressures from legacy products have tempered gains in recent weeks.
MRK Overview and Recent Performance
Merck & Co., Inc. (MRK) is a global leader in pharmaceuticals, known for Keytruda in oncology and Gardasil vaccines. Shares recently traded near $110, reflecting a year-to-date increase of 5.3% but an 8-9% pullback over the past month amid broader sector rotation. With a market cap exceeding $271 billion and a P/E ratio of 15, MRK maintains superior profitability at 28% margins. Performance has been influenced by Keytruda growth expectations and new initiatives like the "Playing with Heart" program on cardiovascular risks, though short-term volatility persists ahead of quarterly results.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots, curated from hundreds available that trade thousands of tickers across various styles, strategies, timeframes, and performance metrics. Out of 351 total bots, 25 elite ones are highlighted as best suited to current market conditions, featuring diverse approaches like swing trading, pattern recognition, and momentum plays with stats including win rates often in the 60-80% range, profit factors above 1.5, and strong risk-adjusted returns. These bots adapt to volatility in stocks like those in biotech and pharma sectors. Explore the page to identify bots aligning with your trading goals and copy top performers for potential edge in dynamic markets.
Head-to-Head Comparison
BIIB and MRK contrast sharply in business models: BIIB's biotech focus on neurology exposes it to higher R&D risks but offers explosive growth from pipeline hits, while MRK's diversified portfolio across oncology, vaccines, and animal health provides steadier revenue. Growth drivers differ—BIIB relies on new MS and rare disease therapies amid legacy erosion, versus MRK's Keytruda dominance and patent cliff preparations. Recent momentum favors BIIB with flat-to-positive monthly moves and superior one-year returns, but MRK edges in stability and dividends. Risks include biotech volatility for BIIB and patent expirations for MRK; market sentiment leans toward BIIB's catalysts short-term.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward BIIB based on stronger trend consistency over the past year, recent analyst upgrades, and pipeline momentum positioning it favorably relative to MRK's pullback. However, MRK remains attractive probabilistically for risk-averse strategies given its scale and yields.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and MRK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- BIIB’s TA Score: 6 bullish, 4 bearish.
- MRK’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -0.01% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.99% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.94%. For the same industry, the average monthly price growth was -2.11%, and the average quarterly price growth was +2.39%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 16, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.94% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | MRK | BIIB / MRK | |
| Capitalization | 28.3B | 280B | 10% |
| EBITDA | 2.7B | 19.4B | 14% |
| Gain YTD | 8.739 | 8.541 | 102% |
| P/E Ratio | 20.58 | 31.95 | 64% |
| Revenue | 9.94B | 65.8B | 15% |
| Total Cash | 4.28B | 5.7B | 75% |
| Total Debt | 6.56B | 49.1B | 13% |
BIIB | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 51 | |
SMR RATING 1..100 | 77 | 47 | |
PRICE GROWTH RATING 1..100 | 16 | 48 | |
P/E GROWTH RATING 1..100 | 13 | 5 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (89) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than BIIB’s over the last 12 months.
MRK's Profit vs Risk Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than BIIB’s over the last 12 months.
MRK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as BIIB (77) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (16) in the Biotechnology industry is in the same range as MRK (48) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as BIIB (13) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.
| BIIB | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | N/A |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 53% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 42% |
| Advances ODDS (%) | 3 days ago 56% | 3 days ago 53% |
| Declines ODDS (%) | 15 days ago 72% | 5 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 51% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PKB | 105.08 | 1.10 | +1.06% |
| Invesco Building & Construction ETF | |||
| RISN | 29.10 | 0.14 | +0.50% |
| Inspire Capital Appreciation ETF | |||
| AOR | 68.97 | 0.19 | +0.28% |
| iShares Core 60/40 Balanced Allc ETF | |||
| GMNY | 49.97 | 0.05 | +0.10% |
| Goldman Sachs Dynamic New Yor Mun IncETF | |||
| BOEU | 39.42 | -4.15 | -9.52% |
| Direxion Daily BA Bull 2X Shares | |||